UniSa - IRIS Institutional Research Information System

PERSICO, Marcello
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 7.631
AS - Asia 7.037
EU - Europa 2.665
SA - Sud America 414
AF - Africa 41
OC - Oceania 15
Continente sconosciuto - Info sul continente non disponibili 6
Totale 17.809
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 7.536
HK - Hong Kong 4.420
SG - Singapore 1.007
CN - Cina 828
UA - Ucraina 632
IT - Italia 561
RU - Federazione Russa 414
BR - Brasile 378
DE - Germania 315
VN - Vietnam 239
IE - Irlanda 237
KR - Corea 213
FI - Finlandia 171
TR - Turchia 154
SE - Svezia 108
CA - Canada 79
GB - Regno Unito 63
IN - India 39
JP - Giappone 33
AT - Austria 30
FR - Francia 30
DK - Danimarca 25
NL - Olanda 24
BD - Bangladesh 19
ZA - Sudafrica 16
ES - Italia 15
TW - Taiwan 14
AU - Australia 11
EC - Ecuador 11
MX - Messico 11
IQ - Iraq 8
PK - Pakistan 8
PL - Polonia 8
AR - Argentina 7
CO - Colombia 6
CZ - Repubblica Ceca 6
DZ - Algeria 6
EU - Europa 6
LT - Lituania 6
UZ - Uzbekistan 6
VE - Venezuela 6
CH - Svizzera 5
SA - Arabia Saudita 5
AE - Emirati Arabi Uniti 4
AZ - Azerbaigian 4
EG - Egitto 4
MA - Marocco 4
NP - Nepal 4
NZ - Nuova Zelanda 4
TN - Tunisia 4
BE - Belgio 3
GR - Grecia 3
ID - Indonesia 3
IR - Iran 3
KE - Kenya 3
MY - Malesia 3
PS - Palestinian Territory 3
RO - Romania 3
TH - Thailandia 3
HN - Honduras 2
IL - Israele 2
JM - Giamaica 2
JO - Giordania 2
KZ - Kazakistan 2
OM - Oman 2
PE - Perù 2
PH - Filippine 2
PY - Paraguay 2
AF - Afghanistan, Repubblica islamica di 1
AL - Albania 1
BG - Bulgaria 1
BH - Bahrain 1
BN - Brunei Darussalam 1
BO - Bolivia 1
BY - Bielorussia 1
CR - Costa Rica 1
GA - Gabon 1
GE - Georgia 1
GY - Guiana 1
HR - Croazia 1
KG - Kirghizistan 1
LB - Libano 1
LV - Lettonia 1
MW - Malawi 1
NO - Norvegia 1
QA - Qatar 1
SN - Senegal 1
UG - Uganda 1
Totale 17.809
Salva come PNG Salva come JPEG
Città #
Hong Kong 4.391
Ann Arbor 1.681
Chandler 838
Jacksonville 819
Princeton 723
Woodbridge 520
Wilmington 366
Singapore 321
Houston 295
Ashburn 255
Dublin 229
Dong Ket 217
Beijing 209
Andover 164
Nanjing 146
Izmir 142
Pellezzano 128
Boardman 120
Moscow 94
Munich 72
Salerno 64
Los Angeles 56
Hebei 55
Shenyang 54
Naples 50
Dallas 49
The Dalles 47
Ottawa 46
Fairfield 45
Changsha 44
Nanchang 42
Norwalk 42
Columbus 41
Jiaxing 39
Düsseldorf 33
Redwood City 33
São Paulo 30
Nuremberg 29
Tianjin 29
Jinan 28
Turku 26
Washington 26
Mestre 25
Brooklyn 23
Tokyo 22
Council Bluffs 20
Falls Church 20
Guangzhou 20
New York 20
Dearborn 19
London 19
Santa Clara 19
San Diego 17
Seattle 17
Belo Horizonte 16
Boston 14
Helsinki 14
Nürnberg 13
Rio de Janeiro 13
Vienna 13
Cambridge 12
Lappeenranta 12
Pune 12
Rome 12
Zhengzhou 12
Copenhagen 11
Johannesburg 11
Montreal 11
San Francisco 11
Amsterdam 10
Fisciano 10
Jinju 10
Milan 10
Phoenix 10
San Jose 10
San Mango Piemonte 10
Brasília 9
Haikou 9
Maletto 9
Stockholm 9
Charlotte 8
Chennai 8
Chicago 8
Dhaka 8
Ha Kwai Chung 7
Pontecagnano 7
San Giorgio A Cremano 7
Shanghai 7
Curitiba 6
Ningbo 6
Saint Petersburg 6
Salvador 6
Secaucus 6
Shenzhen 6
Warsaw 6
Bologna 5
Brno 5
Caxias do Sul 5
Denver 5
Edmonton 5
Totale 13.299
Salva come PNG Salva come JPEG
Nome #
Transfer of innovation on allergic rhinitis and asthma multimorbidity in the elderly (MACVIA-ARIA) - EIP on AHA Twinning Reference Site (GARD research demonstration project) 932
Ombitasvir, paritaprevir, and ritonavir, with or without dasabuvir, plus ribavirin for patients with hepatitis C virus genotype 1 or 4 infection with cirrhosis (ABACUS): a prospective observational study 423
Characterisation of asymptomatic patients and efficacy of preventive measures for SARS-CoV-2 infection in a large population of Southern Italy: a cohort study 396
Mucosal-Associated Invariant T Cells in T-Cell Non-Hodgkin Lymphomas: A Case Series 386
Prospective validation of the CLIP score: a new prognostic system for patient with cirrhosis and hepatocellular carcinoma 298
Impact of telaprevir in HCV patients with cirrhosis and RVR: Real-life data from boceprevir or telaprevir based “triple therapy” experience in southern Italy 297
Non Alcoholic Fatty Liver: Epidemiology and Natural History 293
Validation of the MASK-rhinitis visual analogue scale on smartphone screens to assess allergic rhinitis control 285
Liver biopsy in type 2 diabetes mellitus: Steatohepatitis represents the sole feature of liver damage 280
Hepatitis C virus RNA in serum and liver histology in asymptomatic anti-HCV positive subjects. 226
Hepatic decompensation is the major driver of death in HCV-infected cirrhotic patients with successfully treated early hepatocellular carcinoma 209
Forecasting Hepatitis C liver disease burden on real-life data. Does the hidden iceberg matter to reach the elimination goals? 188
Hepatitis C virus infection in jail: Difficult-to-reach, not to-treat. Results of a point-of-care screening and treatment program 179
Real-life glecaprevir/pibrentasvir in a large cohort of patients with hepatitis C virus infection: The MISTRAL Study 171
Alcoholic Hepatitis: Pathogenesis, Diagnosis and Treatment 166
"Non alcoholic fatty liver disease and eNOS dysfunction in humans" 160
Efficacy and safety of new direct antiviral agents in HCV infected patients with Diffuse Large B Cell Non-Hodgkin Lymphoma 158
18F-fluorodeoxyglucose positron emission tomography/computed tomography in the evaluation of early response in a primary hepatic lymphoma 150
Sustained virological response by direct antiviral agents in HCV leads to an early and significant improvement of liver fibrosis 148
The influence of acute lifestyle changes on NAFLD evolution in a multicentre cohort: a matter of body composition 139
Activation of fetal promoters of insulinlike growth factors II gene in hepatitis C virus-related chronic hepatitis, cirrhosis, and hepatocellular carcinoma. 129
Management of adults with paediatric-onset chronic liver disease: Strategic issues for transition care 128
442 TNF-alpha and IL-10 genetic polymorphisms influence the natural history and the response to antiviral therapy in HCV related chronic hepatitis 126
Hepatocellular carcinoma recurrence in patients with curative resection or ablation: impact of HCV eradication does not depend on the use of interferon. 122
HIGH PREVALENCE OF HEPATITIS C (HCV) INFECTION AND FAVORABLE PROGNOSIS IN PRIMARY HEPATIC LYMPHOMA (PHL) 120
Guidance to 2018 good practice: ARIA digitally-enabled, integrated, person-centred care for rhinitis and asthma 119
Coeliac disease and C virus-related chronic hepatitis: a non association 117
Efficacy and safety of glecaprevir/pibrentasvir in renally impaired patients with chronic HCV infection 115
Pharmacotherapy of alcoholic liver disease in clinical practice 112
A Long-term Treatment with Silybin in Patients with Non-alcoholic Steatohepatitis Stimulates Catalase Activity in Human Endothelial Cells 111
Association between non-alcoholic fatty liver disease, insulin resistance and Helicobacter pylori. 109
Alcoholic Liver Disease and Hepatitis C Chronic Infection 108
Timed regulation of P-Element-Induced Wimpy Testis-interacting RNA expression during rat liver regeneration. 106
Safety and efficacy of ombitasvir/paritaprevir/ritonavir/dasabuvir plus ribavirin in patients over 65 years with HCV genotype 1 cirrhosis 102
A controlled trial on treatment of patients with HCV infection and abnormal liver function tests with or without liver biopsy 99
Antiviral therapy: Why does it fail in HCV-related chronic hepatitis? 98
Age-associated decline of hepatic handling of cholephilic anions in humans is reverted by S-adenosylmethionine (SAMe). 97
Ultrasound-guided fine needle aspiration biopsy of portal vein thrombosis in liver cirrhosis: results in 15 patients. 97
The diagnostic conundrum in non-alcoholic fatty liver disease 96
[629] THE INFLUENCE OF OBESITY AND DIABETES ON CLINICAL AND THERAPEUTICAL OUTCOME IN HCV RELATED CHRONIC HEPATITIS: AN ITALIAN NATIONWIDE SURVEY STUDY (PROBE GROUP) 95
The effect of antiviral therapy on hepatitis C virus-related thrombocytopenia: a case report. 95
Mortality risk according to different clinical characteristics of first episode of liver decompensation in cirrhotic patients: a nationwide, prospective, 3-year follow-up study in Italy. 95
Occult hepatitis B virus infection in patients with non-Hodgkin lymphoma: the need for early diagnosis in anti-Hbc positive patients 94
Risk factors for hospital readmission of elderly patients. 94
[Diabetic neuropathies. IV. Autonomous neuropathy. Peripheral sympathetic innervation and the cardiovascular system]. 93
Untargeted metabolomics as a diagnostic tool in NAFLD: discrimination of steatosis, steatohepatitis and cirrhosis 93
Comparison of disease clusters in two elderly populations hospitalized in 2008 and 2010. 92
The role of fructose in non-alcoholic steatohepatitis: Old relationship and new insights 92
Electrophysiological evidence for Na+-coupled bicarbonate transport in cultured rat hepatocytes 91
A randomized controlled trial of pegylated interferon alpha-2a (40 KD) or interferon alpha-2a plus ribavirin and amantadine vs interferon alpha-2a and ribavirin in treatment-naïve patients with chronic hepatitis C. 91
154 LOW RATE OF ONE-YEAR MORTALITY IN PATIENTS WITH STAGE 4 CIRRHOSIS: THE ITALIAN ASSOCIATION FOR THE STUDY OF LIVER (A.I.S.F.)-EPASCO PROSPECTIVE MULTICENTRE STUDY 91
Controversies about the histological features of chronic HCV patients with persistently normal alanine transaminase levels: what can be done about the present definition? 88
The aetiology of chronic hepatitis in Italy: results from a multicentre national study 88
A randomised controlled trial on pegylated interferon alfa-2a (40kd)(Pegasys) or IFN alfa-2a (ROFERON-A) plus ribavrin (RBV) and amantadine (AMA) vs IFN alfa-2a and RBV in naïve patients with chronic HCV 87
A 15-Yr Prospective Histological Follow-Up Study in Patients With Persistently Normal Aminotransferase Levels (PNAL) Carrying HCV Infection. 86
507 The role of HBV occult infection in patients with non-hodgkin lymphoma: Prevalence and treatment options with nucleotide analogues 86
Corrigendum to "Antiviral therapy after complete response to chemotherapy could be efficacious in HCV-positive non-Hodgkin's lymphoma" [J Hepatol 49 (2008) 557-563] (DOI:10.1016/j.jhep.2008.06.025) 86
Color ultrasound-guided fine needle cutting biopsy for the characterization of diffuse liver damage in critical bone marrow transplanted patients. 84
Epidemiology and Natural History of Alcoholic Liver Disease 83
Antiviral therapy after complete response to chemotherapy could be efficacious in HCV-positive non-Hodgkin's lymphoma. 82
Steatosis as a co-factor in chronic liver diseases 82
A 3-ARM randomized study evaluating the efficacy of triple therapy of pegylated or recombinant interferon alpha-2a 3 MU both combined with ribavirin and amantadine versus dual therapy of recombinant interferon alpha-2a plus ribavirin in naive patients with chronic HCV hepatitis 81
478 Treating chronic hepatitis C in daily practice with PEG-IFN alfa2B and ribavirin. An Italian multicentre study 81
Insulin resistance and liver steatosis in chronic hepatitis C infection genotype 3 80
The epidemiology of non-alcoholic fatty liver disease and its connection with cardiovascular disease: Role of endothelial dysfunction 80
Na+-H+ exchange activity in rat hepatocytes: Role in regulation of intracellular pH 79
Elevated expression and polymorphisms of SOCS3 influence patient response to antiviral therapy in chronic hepatitis C 79
Genetic predictors of response to treatment of chronic hepatitis C virus infection in patients from southern Italy 79
FN 44 HEPATIC RETINOL BINDING PROTEIN 4 (RBP-4) LEVELS ARE SIGNIFICANTLY RELATED TO THE STEATOHEPATITIS GRADE (COMPROMISSION) BUT NOT WITH HCV INFECTION 78
Retrospective, observational, multicentre study on an Italian population affected by chronic hepatitis C who failed to clear HCV-RNA after the combined therapy (PEG-IFN and ribavirin): NADIR study. 78
Etiology of newly-diagnosed cases of chronic liver disease in Southern Italy: Results of a prospective multicentric study 78
Endocan Serum Levels in Patients with Non-Alcoholic Fatty Liver Disease with or without Type 2 Diabetes Mellitus: A Pilot Study 78
Steatohepatitis is associated with diabetes and fibrosis in genotype 1b HCV-related chronic liver disease 77
Abnormal hepatic uptake of low doses of sulfobromophthalein in Gilbert's syndrome: the role of reduced affinity of the plasma membrane carrier of organic anions. 77
93 HCV genotype 2 and 3 can be cured by PEG-IFN-alfa-2B and RBV for 12 wks: A randomized controlled study 76
Vascular endothelial dysfunction in inflammatory bowel diseases: Pharmacological and nonpharmacological targets 76
Diagnosis of chronic liver disease: reproducibility and validation of liver biopsy. 75
Chronic liver disease and lymphoproliferative disorders in HCV-positive patients: a working hypothesis. 75
Sustained virological response to interferon-alpha is associated with improved outcome in HCV-related cirrhosis: a retrospective study. 75
Clinical expression of insulin resistance in hepatitis C and B virus-related chronic hepatitis: differences and similarities. 74
Familial clustering of heterogeneous chronic unconjugated hyperbilirubinemia. 74
Alanine aminotransferase measurements and histological disease in hepatitis C. 74
The role of bright liver echo pattern on ultrasound B-mode examination in the diagnosis of liver steatosis. 72
Regional distribution of transforming growth factor-alpha and epidermal growth factor in normal and portal hypertensive gastric mucosa in humans. 72
Hepatic uptake of organic anions affects the plasma bilirubin level in subjects with Gilbert's syndrome mutations in UGT1A1. 72
The importance of HCV on burden of chronic liver disease in Italy: A multicenter prevalence study of 9,997 cases 72
Real-life effectiveness and safety of Glecaprevir/Pibrentasvir in HCV infected patients with chronic kidney disease 72
Clinical management of HCV carriers with normal aminotransferase levels. 71
Management of the HBV reactivation in isolated HBcAb positive patients affected with Non Hodgkin Lymphoma. 71
Long-term liver histology improvement in patients with chronic hepatitis B and sustained response to interferon 71
Role of Oxidative Stress in Pathophysiology of Nonalcoholic Fatty Liver Disease 71
Lack of correlation between serum anti-HBcore detectability and hepatocellular carcinoma in patients with HCV-related cirrhosis. 70
The clinical significance of occult HBV infection in acute delta virus hepatitis in a case of immunosuppressive therapy for non-Hodgkin lymphomas. 70
Practice guidelines for the treatment of hepatitis C: recommendations from an AISF/SIMIT/SIMAST Expert Opinion Meeting. 70
Erratum to: HBV and HCV infection in type 2 diabetes mellitus: a survey in three diabetes units in different Italian areas 70
Tamoxifen in the treatment of hepatocellular carcinoma: 5-year results of the CLIP-1 multicentre randomised controlled trial. 70
Dissociation between vascular and metabolic effects of nicotinic acid in Gilbert's syndrome. 69
[Hepatorenal syndrome. Clinical and pathogenetic aspects and therapeutic approach]. 69
Dose dependence of nicotinic acid-induced hyperbilirubinemia and its dissociation from hemolysis in Gilbert's syndrome. 68
[Diabetic neuropathy. II. Autonomic neuropathy. The gastrointestinal system]. 68
Totale 12.455
Salva come PNG Salva come JPEG
Categoria #
all - tutte 65.458
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 65.458
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/20211.239 0 126 139 20 149 52 160 13 135 12 180 253
2021/20221.248 6 3 8 6 26 24 34 58 193 169 156 565
2022/20232.009 207 118 63 237 291 430 12 185 301 5 108 52
2023/2024890 82 120 69 32 71 140 32 44 8 34 51 207
2024/20252.756 73 46 56 118 152 290 434 323 486 170 291 317
2025/20264.815 1.663 3.152 0 0 0 0 0 0 0 0 0 0
Totale 18.178